Oruka Therapeutics to Be Added to the Nasdaq Biotechnology Index (NBI)
Oruka Therapeutics to Be Added to the Nasdaq Biotechnology Index (NBI)
MENLO PARK, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (Nasdaq: ORKA), a biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced that it is expected to be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the "NBI"). Oruka's addition will become effective prior to market open on Monday, December 23rd, 2024.
加利福尼亞州門羅公園，2024年12月18日（全球新聞網絡）-- Oruka Therapeutics, Inc.（「Oruka」）（納斯達克：ORKA），是一家開發新型生物製品的生物技術公司，旨在爲包括斑塊性銀屑病在內的慢性皮膚疾病的治療設定新的標準。今天宣佈，Oruka預計將被納入納斯達克生物技術指數（納斯達克：NBI）（「NBI」）。Oruka的加入將在2024年12月23日（星期一）市場開盤前生效。
The NBI is designed to track the performance of a set of securities listed on The Nasdaq Stock Market that are issued by companies classified as either biotechnology or pharmaceutical companies according to the Industry Classification Benchmark. Companies in the NBI must meet certain eligibility requirements, including, but not limited to, minimum market capitalization, average daily trading volume, and seasoning as a public company. The NBI is evaluated annually in December and is calculated under a modified capitalization-weighted methodology.
NBI旨在跟蹤在納斯達克證券市場上市的證券的表現，這些證券由根據行業分類基準分類爲生物技術或藥品公司的公司發行。NBI中的公司必須滿足某些資格要求，包括但不限於最低市值、平均每日成交量和作爲上市公司的調味品。NBI每年在12月進行評估，並根據修改的市值加權方法進行計算。
For more information about the NBI, visit:
有關NBI的更多信息，請訪問：
About Oruka Therapeutics
關於Oruka Therapeutics
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit and follow Oruka on LinkedIn.
Oruka Therapeutics is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. Oruka's mission is to offer patients suffering from chronic skin diseases like plaque psoriasis the greatest possible freedom from their condition by achieving high rates of complete disease clearance with dosing as infrequently as once or twice a year. Oruka is advancing a proprietary portfolio of potentially best-in-class antibodies that were engineered by Paragon Therapeutics and target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. For more information, visit and follow Oruka on LinkedIn.
Investor Contact:
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
投資者聯繫：
Alan Lada
(650)-606-7911
alan.lada@orukatx.com
譯文內容由第三人軟體翻譯。
